Clinical Trials Logo

Clinical Trial Summary

This research study involves a combination of three drugs given together as a possible treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either INI-1 (SMARCB1) or SMARCA4. The names of the study drugs involved in this study are: - Tazemetostat (TAZVERIK) - Nivolumab (OPDIVO) - Ipilimumab (YERVOY)


Clinical Trial Description

This research study involves a combination of three drugs given together as a possible treatment for these types of cancers. One drug is small molecule inhibitor targeting EZH2 (tazemetostat) and two are immunotherapeutic checkpoint inhibitors (nivolumab and ipilimumab). This is a Phase I/II clinical trial. Phase I clinical trials test the safety of an investigational drug, or combination of drugs, and tries to define the appropriate dose of the investigational drugs to use for further studies. Phase II clinical trials test the safety and effectiveness of an investigational drug, or drug combination, to learn whether the drug or drug combination works in treating a specific disease. "Investigational" means that the drug combination is being studied. This trial is studying the combination of tazemetostat, nivolumab, and ipilimumab in two parts: - Part 1: To find the safest dose of these three study drugs in combination for children with INI1- (or SMARCA4-) negative cancers who have completed upfront treatment - Part 2: To determine whether this combination can effectively treat INI1- or SMARCA4-negative cancers The research study procedures include screening for eligibility study treatment, evaluation and follow-up visits. Participants will be asked to provide blood samples and undergo procedures that might be different from a regular medical examination. There are additional research samples that participants will be asked to consent for their collection. Participants will receive study treatment for up to 2 years, as long as there is benefit or there are no serious side effects. Participants will be followed for approximately 2 years after stopping treatment. It is expected that about 49 people will take part in this research study. The U.S. Food and Drug Administration (FDA) has not approved this combination of three drugs for this specific disease. However, tazemetostat has been approved for use in epithelioid sarcoma (an INI1-deficient tumor), and the combination of nivolumab and ipilimumab has also been approved for other uses. Separately, tazemetostat and the combination of nivolumab and ipilimumab have also been tested in children and the safest doses of each drug (and the combination for nivolumab and ipilimumab) have been determined. Bristol-Myers Squibb and Epizyme, two pharmaceutical companies, are supporting this study by providing the study drugs. Dana-Farber Cancer Institute is also supporting this study by providing funding. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05407441
Study type Interventional
Source Dana-Farber Cancer Institute
Contact Susan Chi, MD
Phone (617) 632-4386
Email susan_chi@dfci.harvard.edu
Status Recruiting
Phase Phase 1/Phase 2
Start date August 10, 2023
Completion date February 1, 2029

See also
  Status Clinical Trial Phase
Completed NCT03955042 - Pemetrexed for the Treatment of Chordoma Phase 1
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Active, not recruiting NCT00496119 - Proton Beam Therapy for Chordoma Patients Phase 2
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Completed NCT03595228 - BN Brachyury and Radiation in Chordoma Phase 2
Recruiting NCT06140732 - Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma Phase 2
Active, not recruiting NCT01175109 - Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma Phase 1
Completed NCT00150072 - Efficacy and Safety of Imatinib in Chordoma Phase 2
Terminated NCT00003926 - Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Phase 1
Recruiting NCT05041127 - Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma Phase 2
Recruiting NCT05861245 - Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base N/A
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Completed NCT02383498 - QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma Phase 2
Recruiting NCT03242382 - Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. Phase 2
Completed NCT02520128 - A Study of IMRT in Primary Bone and Soft Tissue Sarcoma N/A
Recruiting NCT01567046 - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas N/A
Recruiting NCT02986516 - Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease N/A
Completed NCT00919269 - Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Active, not recruiting NCT02989636 - Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Phase 1
Active, not recruiting NCT03083678 - Afatinib in Locally Advanced and Metastatic Chordoma Phase 2